Innovative tools and methods for toxicity testing within PARC work package 5 on hazard assessment.
NAMs
NGRA
PARC
hazard assessment
human health
Journal
Frontiers in toxicology
ISSN: 2673-3080
Titre abrégé: Front Toxicol
Pays: Switzerland
ID NLM: 101777990
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
05
2023
accepted:
10
07
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
New approach methodologies (NAMs) have the potential to become a major component of regulatory risk assessment, however, their actual implementation is challenging. The European Partnership for the Assessment of Risks from Chemicals (PARC) was designed to address many of the challenges that exist for the development and implementation of NAMs in modern chemical risk assessment. PARC's proximity to national and European regulatory agencies is envisioned to ensure that all the research and innovation projects that are initiated within PARC agree with actual regulatory needs. One of the main aims of PARC is to develop innovative methodologies that will directly aid chemical hazard identification, risk assessment, and regulation/policy. This will facilitate the development of NAMs for use in risk assessment, as well as the transition from an endpoint-based animal testing strategy to a more mechanistic-based NAMs testing strategy, as foreseen by the Tox21 and the EU Chemical's Strategy for Sustainability. This work falls under work package 5 (WP5) of the PARC initiative. There are three different tasks within WP5, and this paper is a general overview of the five main projects in the Task 5.2 '
Identifiants
pubmed: 37538785
doi: 10.3389/ftox.2023.1216369
pii: 1216369
pmc: PMC10395075
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1216369Informations de copyright
Copyright © 2023 De Castelbajac, Aiello, Arenas, Svingen, Ramhøj, Zalko, Barouki, Vanhaecke, Rogiers, Audebert, Oelgeschlaeger, Braeuning, Blanc, Tal, Rüegg, Fritsche, Marx-Stoelting and Rivière.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Toxicol. 2020 Aug;94(8):2899-2923
pubmed: 32594184
Arch Toxicol. 2023 Mar;97(3):893-908
pubmed: 36645448
Toxicol Sci. 2006 Jan;89(1):51-6
pubmed: 16221960
Environ Health Perspect. 2016 May 1;124(5):A81-3
pubmed: 27135406
Reprod Toxicol. 2017 Mar;68:3-33
pubmed: 27760374
Regul Toxicol Pharmacol. 2018 Feb;92:1-7
pubmed: 29113941
Environ Health Perspect. 2019 Sep;127(9):95001
pubmed: 31487205
Int J Mol Sci. 2020 Apr 28;21(9):
pubmed: 32354186
Endocrinology. 2020 Oct 1;161(10):
pubmed: 32615585
Int J Mol Sci. 2020 May 14;21(10):
pubmed: 32423144
Mol Cell Endocrinol. 2020 May 15;508:110779
pubmed: 32147522
Int J Mol Sci. 2020 Apr 24;21(8):
pubmed: 32344727
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340264
Crit Rev Toxicol. 2014 Jan;44(1):64-82
pubmed: 24180433